This is in line with previous findings for EGFR-targeting diabody-scTRAIL fusion proteins (Db-scTRAIL) and dimeric EHD2-scTRAIL fusion proteins, all exhibiting very strong tumor cell killing activity with subnanomolar EC50values, although different pharmacokinetic properties22–24. The gene discussed is EHD2; the disease is neoplasm.